Drugs / TINLORAFENIB
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05349864 | Jun → Sep 2022 | — | Pfizer | Completed | No outcome recorded |
| Phase 1 | NCT04543188 | Jan 2021 → Mar 2024 | melanoma, non-small cell lung carcinoma, primary brain neoplasm | Pfizer | Terminated | No outcome recorded |
Evidence & citations 8 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TINLORAFENIB | ChEMBL registry synonym — accepted as the source's own label CHEMBL5095256 ↗ |
| Known as | AR00504461 | ChEMBL registry synonym — accepted as the source's own label CHEMBL5095256 ↗ |
| Known as | ARRY-461 | ChEMBL registry synonym — accepted as the source's own label CHEMBL5095256 ↗ |
| Known as | PF-07284890 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05349864 ↗ |
| Action | Inhibit | “BRAFV600E inhibitor” PMID 39077892 ↗ Jul 2024 |
| Modality | Small molecule | — CHEMBL5095256 ↗ |
| Route | Oral | “PF-07284890 will be administered orally” NCT04543188 ↗ |
| Target | BRAF | “the brain-penetrant BRAFV600E inhibitor PF-07284890” PMID 39077892 ↗ Jul 2024 |